Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO

William Hearl - CEO, Chairman of the Board, and Founder of Immunic Therapeutics
Published on :

Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising [….]

Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board

Published on :

Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board ROCKVILLE, Md.–(BUSINESS WIRE)– Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced [….]

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development

Published on :

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, [….]

Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President [….]